-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Read: Through Best's acquisition, Uniter will strengthen its growth in China, the world's second-largest pharmaceutical market.
, August 25, 2020, Paris, France, Jiangsu, China: The global leader in sterile single-dose preparations, France's Unitel Pharmaceuticals launched the acquisition of Chinese pharmaceutical company Nanjing Renian Best Pharmaceutical Co., Ltd.
acquisition of Best, Uniter will strengthen its growth in China, the world's second-largest pharmaceutical market, and complement its industrial base outside Europe, the United States and Brazil.
Goupil, chief executive of Unitel, explained: "We are delighted to welcome this new company to the Unitel Group, which will enable us to conduct processing operations in China.
this is in line with our strategy of producing close to the final market.
acquisition, Unitel will provide services to local and multinational pharmaceutical companies developing the ophthalmology and respiratory markets in China, producing sterile, preservative-free single-dose preparations in China.
About Nanjing Renian Best Pharmaceutical Co., Ltd. Nanjing Renian Best Pharmaceutical Co., Ltd. is a pharmaceutical company located in Nanjing City, Jiangsu Province, focusing on solid and liquid preparation production, turnover of 10 million euros, with 130 employees.
an important asset of Wuxi Jinyuan Industrial Investment and Development Group Co., Ltd., a government investment platform belonging to Wuxi Binhu District.
about Younitel Pharmaceuticals Group was founded in 1993 through the acquisition of a 17-employee plant in Amiens, France.
is now a global leader in pharmaceutical manufacturing, producing sterile single-dose preparations and strip bagged preparations, including eye drops, nasal care fluids and atomized inhalation drugs, for original and generic customers.
group has six production sites and an innovation research and development center in France, the United States and Brazil, with a turnover of 319 million euros in 2019.
Group currently has more than 1,500 employees and continues to strengthen its global leadership in the production of blow-sealed sterile preparations.
March 2017, Unitel Completed its fourth capital acquisition, which was acquired by Ardian, Keensight Capital, and Park capital from former shareholder Equistone Partners Europe and management.
.